Education
About Us
Working with TipRanks
Follow Us
Natera (NTRA)
NASDAQ:NTRA
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.57Last Year’s EPS
-0.3Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -1.52%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong performance for Natera, with significant revenue growth, volume increases across key segments, and positive cash flow. Despite minor challenges such as weather disruptions and some uncertainty in ASP improvements, the company's strategic initiatives in diagnostics and oncology are bearing fruit, leading to an optimistic outlook.Company Guidance
During Natera's 2025 first-quarter financial results conference call, the company provided robust guidance driven by significant growth across various metrics. Revenue reached $502 million, marking a 37% increase year-over-year, with 855,000 units processed. Signatera's clinical volumes rose by 52% year-on-year. Gross margins were at 63%, with an improvement of over 110 basis points compared to Q4 2024. The company generated $23 million in cash and raised its annual revenue guidance to a range of $1.94 billion to $2.02 billion, indicating a 26% year-over-year growth excluding true-ups. Strategic highlights included advancements in clinical studies, specifically in heart transplantation and breast cancer, and continued expansion in oncology, with a focus on data-driven growth and reimbursement strategies.Record Revenue Growth
Natera generated $502 million in revenue this quarter compared to $368 million in the previous year, representing approximately 37% growth.
Signatera Volume Surge
Signatera clinical volumes grew 52% year-on-year with a sequential increase of 16,500 units, marking the best sequential unit quarter yet.
Women's Health and Organ Health Expansion
Women's Health volumes grew by more than 40,000 units sequentially, while Organ Health saw over 50% year-on-year growth.
Gross Margin Improvement
Gross margins were 63% for the quarter, with an improvement of more than 110 basis points compared to the previous quarter.
Prospera and DQS Study Success
The DEFINE study showed Prospera's ability to predict clinical outcomes in heart transplantation, outperforming biopsy in predicting graft dysfunction.
Positive Cash Flow
Natera generated $23 million in cash, even with increased investments in growth opportunities.
---
NTRA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NTRA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 08, 2025 | $162.57 | ― | ― |
| Feb 27, 2025 | $156.61 | $155.59 | -0.65% |
| Nov 12, 2024 | $135.12 | $160.97 | +19.13% |
| Aug 08, 2024 | $107.70 | $114.57 | +6.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Natera (NTRA) report earnings?
Natera (NTRA) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Natera (NTRA) earnings time?
Natera (NTRA) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NTRA EPS forecast?
NTRA EPS forecast for the fiscal quarter 2025 (Q2) is -0.57.
---